The Stowe Foundation of Illinois has been given a tremendous opportunity by Extracellular Concepts to participate in the advance of Regenerative Medicine for MS. Attached is a published paper in ACS Nano, a peer reviewed publication of the American Chemical Society.The paper establishes all the scientific merits of the technology platform. It is at the forefront of Regenerative Medicine. It is a good fit for the advancement of Applied BioLogics. The next step to gain regulatory approval for the MS product is to do a large clinical trial on mice at the Oklahoma State University School of Veterinary Medicine. They have a stellar reputation.within the medical community. There are two products that need to be tested.
One exosome product provides a therapeutic benefit for advanced MS patients, the other is an MS Vaccine to prevent MS. The mice studies have to be completed before you can do a phase I human clinical trial. The phase I human trials would be done at Oklahoma University Medical school. Right now the objective is to get the two mice studies completed. The Stowe Foundation of Illinois will provide $500,000 to complete the animal studies. Oklahoma State is preparing the protocols to be followed. We should be able to raise that on the Cloud or from Philanthropic donors interested in MS. When you see the video in the second email, you will understand why these products need to get through the regulatory approval process. To permanently reverse MS will still require Applied BioLogics.However the exomoses appear to be the Rosetta Stone.
regards, Lawrence Stowe Founder and Managing Director Stowe Foundation of Illinois
Reza-Paper-ACS-Nano.pdf